Key Players
Competitive Landscape
Four supplier models compete in the HDAC inhibitors market: originator pharmaceutical groups, generic injectable manufacturers, regional selective-inhibitor developers and clinical-stage precision-medicine companies. Approved labels provide immediate access, while selective programs compete on indication evidence and tolerability.
Competitive investment has moved in two directions since 2025: geographic access for approved oral products and broader clinical evidence for selective inhibitors. Italfarmaco secured Health Canada priority review for givinostat in June 2026, with a targeted 180-day review. Shenzhen Chipscreen Biosciences completed a 423-patient Phase III analysis in July 2025 that met the primary event-free survival endpoint. Price remains relevant, but treatment centers first compare label breadth, monitoring burden and reimbursement access.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Italfarmaco, Health Canada accepted givinostat for priority review in June 2026 with a 180-day target. | Canadian DMD centers need a mutation-independent oral option with defined monitoring. | Approved HDAC therapies are moving into additional national review systems. | A Canadian approval would support specialist distribution and local access agreements. |
| Italfarmaco and JCR Pharmaceuticals signed a Japan commercialization agreement in December 2025. | Japanese market entry requires local clinical, regulatory and distribution execution. | Rare-disease originators are using regional partners to extend approved products. | Revenue is available from Japanese development milestones and commercial sales after approval. |
| Shenzhen Chipscreen Biosciences completed the 423-patient chidamide DEB Phase III analysis in July 2025. | Hematology teams need stronger first-line evidence for MYC/BCL2 double-expressor DLBCL. | Subtype-selective HDAC therapy is moving from relapsed care into frontline combinations. | Regulatory conversion can support combination treatment and oral maintenance demand in China. |
Merck & Co., Inc., Acrotech Biopharma Inc., Fresenius Kabi USA, LLC, HUYA Bioscience International, LLC, IngenOx Therapeutics and Tenaya Therapeutics, Inc. compete on current labels, formulation, licensing or clinical evidence. No additional qualifying 2025-2026 events are mapped for them in this section.
Source: Future Market Insights, HDAC Inhibitors Market and Chromatin Modifiers Market Reports, 2026-2036.
Italfarmaco and Shenzhen Chipscreen Biosciences together cover rare-disease oral therapy, subtype-selective oncology, regional licensing and reimbursement expansion. Acrotech Biopharma and Fresenius Kabi add hospital-administered injectable formats.
Who leads the HDAC inhibitors market?
Italfarmaco has the broadest recent cross-region expansion based on USA, UK and EU approvals plus Canadian priority review. Shenzhen Chipscreen Biosciences competes through marketed subtype-selective chidamide across lymphoma indications and Asian licensing routes.
Which suppliers have documented regulatory approvals?
Italfarmaco holds approvals for oral givinostat across major Western markets. Merck supplies oral vorinostat, while Acrotech Biopharma and Fresenius Kabi supply approved injectable belinostat or romidepsin. Shenzhen Chipscreen Biosciences supplies approved oral chidamide in Asian markets.
Which companies provide oral and injectable HDAC products?
Italfarmaco, Merck and Shenzhen Chipscreen Biosciences provide oral HDAC therapies. Acrotech Biopharma and Fresenius Kabi provide intravenous products for specialist oncology use. HUYA Bioscience International holds regional chidamide rights, while IngenOx and Tenaya develop selective oral candidates.
Which suppliers serve North America, Europe and East Asia?
Italfarmaco serves North America and Europe and has assigned Japanese development and commercialization rights to JCR Pharmaceuticals. Shenzhen Chipscreen Biosciences supplies China and licenses chidamide outside China. HUYA Bioscience International supports Japan and multiregional development, while IngenOx runs trials across the United Kingdom and Asia.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Italfarmaco S.p.A. | North America, Europe and planned Asian access | Oral givinostat for Duchenne muscular dystrophy including Canadian priority review and Japanese commercialization agreement. |
| Merck & Co., Inc. | North America | Oral vorinostat for cutaneous T-cell lymphoma after previous systemic treatment. |
| Acrotech Biopharma Inc. | North America | Intravenous belinostat for relapsed or refractory peripheral T-cell lymphoma. |
| Fresenius Kabi USA, LLC | North America | Generic intravenous romidepsin for cutaneous T-cell lymphoma in specialist hospital settings. |
| Shenzhen Chipscreen Biosciences Co., Ltd. | China, Japan and licensing markets | Oral subtype-selective chidamide across PTCL and DLBCL pathways plus combination development. |
| HUYA Bioscience International, LLC | Japan and multiregional trials | Hiyasta commercialization in Japan and HBI-8000 combination development outside China. |
| IngenOx Therapeutics | United Kingdom and Asian trials | Oral zabadinostat combinations in Phase II oncology studies for resistant solid tumors. |
| Tenaya Therapeutics, Inc. | North America | Selective HDAC6 inhibitor TN-301 with Phase I safety data and DMD or cardiac development plans. |
Research Methodology
The companies in this section illustrate market structure and do not form a ranking. A company appears where current evidence confirms an approved HDAC product, regional commercialization right or active HDAC clinical program. Evidence includes regulator records, prescribing information, company announcements and clinical updates. Approvals belong to the named product holder or legal entity. The 44.0% pan-HDAC share is an FMI estimate for 2026.
